20 related articles for article (PubMed ID: 38644271)
1. Lectin-nanoparticle concept for free PSA glycovariant providing superior cancer specificity.
Kekki H; Montoya Perez I; Taimen P; Boström PJ; Gidwani K; Pettersson K
Clin Chim Acta; 2024 Jun; 559():119689. PubMed ID: 38677453
[TBL] [Abstract][Full Text] [Related]
2. Elevation of Serum Prostate-Specific Antigen Levels in Males With Pulmonary Embolism.
Peng YF; Ma LY; Luo M
Clin Appl Thromb Hemost; 2024; 30():10760296241250002. PubMed ID: 38779806
[TBL] [Abstract][Full Text] [Related]
3. External validation of an artificial neural network and two nomograms for prostate cancer detection.
Ecke TH; Hallmann S; Koch S; Ruttloff J; Cammann H; Gerullis H; Miller K; Stephan C
ISRN Urol; 2012; 2012():643181. PubMed ID: 22830050
[TBL] [Abstract][Full Text] [Related]
4. The Optimal Cut-Off Value of Blood Stasis Syndrome Score in BSS Diagnosis in Korea.
Kang BK; Park TY; Jung J; Ko M; Lee MS; Lee JA
Evid Based Complement Alternat Med; 2017; 2017():8049481. PubMed ID: 29085435
[TBL] [Abstract][Full Text] [Related]
5. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
6. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
7. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
8. Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).
Martin BJ; Finlay JA; Sterling K; Ward M; Lifsey D; Mercante D; Jainto JM; Martin L; Rayford W
Prostate Cancer Prostatic Dis; 2004; 7(2):132-7. PubMed ID: 15007379
[TBL] [Abstract][Full Text] [Related]
9. [Early diagnosis of prostate cancer using free/total prostate-specific antigen ratio with population-based screening data].
Zhang L; Ji G; Li X; Wang W; Gao H; Pan Y; Wang H; Masaaki K; Zhao X
Zhonghua Nan Ke Xue; 2004 Aug; 10(8):582-5. PubMed ID: 15362518
[TBL] [Abstract][Full Text] [Related]
10. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
11. [Exploration and validation of optimal cut-off values for tPSA and fPSA/tPSA screening of prostate cancer at different ages].
Liu XM; Duan HY; Zhang DQ; Chen C; Ji YT; Zhang YM; Feng ZW; Liu Y; Li JJ; Zhang Y; Li CY; Zhang YC; Yang L; Lyu ZY; Song FF; Song FJ; Huang YB
Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):354-364. PubMed ID: 38644271
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
